Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.
Routes to making life-saving medications and other pharmaceutical compounds are among the most carefully protected trade secrets in global industry.
A new antibiotic developed by a Flinders University researcher is being heralded as a breakthrough in the war against a drug resistant superbug.
Researchers at Johns Hopkins Medicine say they have added to evidence that rapid resistance gene sequencing technology can accurately speed the identification of specific antibiotic-resistant bacteria strains that sicken and kill some patients.
A team of scientists from the MISiS National University of Science and Technology with colleagues from the Central European Institute of Technology and other Czech universities have developed a biodegradable material with antibacterial action to use as a dressing on damaged skin.
This study looked at trends over time in oral antibiotic prescribing by dermatologists using commercial insurance claims data for almost 986,000 courses of oral antibiotics prescribed by nearly 12,000 dermatologists.
Microbes are often seen as pathogens that cause disease and antibiotics have been used successfully to combat these foreign invaders. In reality, the picture is more complex.
A new Northwestern Medicine study found only 13 percent of outpatient antibiotic prescriptions were appropriate, with 36 percent considered potentially appropriate.
The metabolic protein AMPK has been described as a kind of magic bullet for health. Studies in animal models have shown that compounds that activate the protein have health-promoting effects to reverse diabetes, improve cardiovascular health, treat mitochondrial disease--even extend life span.
A University of Wisconsin-Madison researcher and his collaborators at the University of California, San Francisco have repurposed the gene-editing tool CRISPR to study which genes are targeted by particular antibiotics, providing clues on how to improve existing antibiotics or develop new ones.
The Staphylococcus aureus bacterium is one of the commonest pathogens and can even cause sepsis. The new antibiotic dalbavancin is very effective against many bacterial pathogens.
Spotless surfaces in hospitals can hide bacteria that rarely cause problems for healthy people but pose a serious threat to people with weakened immune systems.
Mutant bacteria stranded in space by visiting astronauts have been adapting to survive in their new environment, according to a new study.
Two new species of bacteria have been found in the blood of patients in China.
The U.S. Food and Drug Administration has accepted an Investigational New Drug application by physician-scientists at University of California San Diego School of Medicine to conduct the first U.S. clinical trial of an intravenously administered bacteriophage-based therapy.
Patients with cystic fibrosis are often infected by pseudomonas aeruginosa, a bacterium that infects the lungs and prevents breathing, often causing death.
Increased levels of antibiotic-resistant bacteria in the environment may have different causes. It could be a consequence of on-site selection from antibiotic residues in the environment, hence promoting the evolution of new forms of resistance.
Researchers from LSTM and the University of Liverpool have successfully optimized a hit from a whole cell screening of a 10000-compound library to deliver the first novel fully synthetic and rationally designed anti-Wolbachia drug, AWZ1066S, which could potentially be used to treat onchocerciasis and lymphatic filariasis.
A research team led by scientists at the Columbia University Mailman School of Public Health report on a new method to help health officials control outbreaks of methicillin-resistant Staphylococcus aureus, or MRSA, a life-threatening antibiotic-resistant infection often seen in hospitals.
New developments in antimicrobial peptides (AMPs) with antibiofilm properties are rapidly materializing.
A team of doctors led by Karen L. Kotloff, M.D., University of Maryland School of Medicine, Center for Vaccine Development and Global Health, has performed a clinical trial involving multiple hospitals that tested the effectiveness of applying a topical antibiotic known as mupirocin for prevention of Staphylococcus aureus infection in babies in the neonatal intensive care unit.